TW202227096A - 醫藥組合物及使用其治療癌症之方法 - Google Patents

醫藥組合物及使用其治療癌症之方法 Download PDF

Info

Publication number
TW202227096A
TW202227096A TW110139922A TW110139922A TW202227096A TW 202227096 A TW202227096 A TW 202227096A TW 110139922 A TW110139922 A TW 110139922A TW 110139922 A TW110139922 A TW 110139922A TW 202227096 A TW202227096 A TW 202227096A
Authority
TW
Taiwan
Prior art keywords
venetoclax
dosage form
chidaridine
effective amount
decitabine
Prior art date
Application number
TW110139922A
Other languages
English (en)
Chinese (zh)
Inventor
金賢 道
哈洛德 科爾
阿拉姆 奧加尼西亞
Original Assignee
日商大塚製藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商大塚製藥股份有限公司 filed Critical 日商大塚製藥股份有限公司
Publication of TW202227096A publication Critical patent/TW202227096A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
TW110139922A 2020-10-29 2021-10-27 醫藥組合物及使用其治療癌症之方法 TW202227096A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063107010P 2020-10-29 2020-10-29
US63/107,010 2020-10-29

Publications (1)

Publication Number Publication Date
TW202227096A true TW202227096A (zh) 2022-07-16

Family

ID=81384423

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110139922A TW202227096A (zh) 2020-10-29 2021-10-27 醫藥組合物及使用其治療癌症之方法

Country Status (10)

Country Link
US (1) US12697347B2 (enExample)
EP (1) EP4237094A4 (enExample)
JP (2) JP2023548303A (enExample)
KR (1) KR20230097034A (enExample)
CN (2) CN122182592A (enExample)
AU (1) AU2021369508B2 (enExample)
CA (1) CA3188316A1 (enExample)
MX (1) MX2023003305A (enExample)
TW (1) TW202227096A (enExample)
WO (1) WO2022093930A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023548303A (ja) 2020-10-29 2023-11-16 大塚製薬株式会社 癌を処置する為の医薬組成物及びその使用方法
AU2024265282A1 (en) * 2023-05-02 2025-12-18 Taiho Pharmaceutical Co., Ltd. Response-based dosing for treating cancer with a hypomethylating agent and cedazuridine

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2708264C (en) 2007-12-10 2018-07-03 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders
US9834576B2 (en) 2013-10-29 2017-12-05 Otsuka Pharmaceutical Co., Ltd. Synthetic route to 2′-deoxy-2′,2′-difluorotetrahydrouridines
US10683552B2 (en) 2014-11-25 2020-06-16 Presidents And Fellows Of Harvard College Clonal haematopoiesis
US11224610B2 (en) 2018-09-19 2022-01-18 Otsuka Pharmaceutical Co., Ltd. Low dose combination CDA substrate drug/cedazuridine with extended administration
SG11202108523UA (en) * 2019-03-25 2021-09-29 Otsuka Pharma Co Ltd Antitumor composition
MX2022005811A (es) 2019-11-13 2022-06-08 Taiho Pharmaceutical Co Ltd Sal novedosa de compuesto de terfenilo.
WO2021113688A1 (en) 2019-12-05 2021-06-10 Sumitomo Dainippon Pharma Oncology, Inc. Combination therapies for treatment of myelodysplastic syndrome
EP4090335A1 (en) 2020-01-17 2022-11-23 Novartis AG Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
LT4069254T (lt) 2020-02-25 2024-10-10 Otsuka Pharmaceutical Co., Ltd. Kietos geriamosios vaisto formos, apimančios decitabiną ir cedazuridiną
JP2023548303A (ja) 2020-10-29 2023-11-16 大塚製薬株式会社 癌を処置する為の医薬組成物及びその使用方法
JP2024521824A (ja) 2021-05-27 2024-06-04 ヴァンダービルト ユニヴァーシティ マクロライド化合物
MX2024003537A (es) 2021-09-21 2024-05-03 Otsuka Pharma Co Ltd Metodos de tratamiento de los sindrome mielodisplasico con decitabina y cedazuridina.

Also Published As

Publication number Publication date
JP2023548303A (ja) 2023-11-16
CN116018145A (zh) 2023-04-25
KR20230097034A (ko) 2023-06-30
CA3188316A1 (en) 2022-05-05
AU2021369508B2 (en) 2026-07-09
US20230405037A1 (en) 2023-12-21
US12697347B2 (en) 2026-08-04
WO2022093930A1 (en) 2022-05-05
JP2026083415A (ja) 2026-05-19
MX2023003305A (es) 2023-04-13
AU2021369508A1 (en) 2023-03-02
CN122182592A (zh) 2026-06-12
EP4237094A4 (en) 2024-07-10
EP4237094A1 (en) 2023-09-06

Similar Documents

Publication Publication Date Title
ES2627820T3 (es) Formulaciones de inhibidor de histona desacetilasa en combinación con bendamustina y usos de las mismas
JP7742841B2 (ja) デシタビンとセダズリジンとの組み合わせの固形経口剤形
JP2026083415A (ja) 癌を処置する為の医薬組成物及びその使用方法
JP2021514975A (ja) サイクリン依存性キナーゼ阻害剤およびｂｅｔ−ブロモドメイン阻害剤の組合せ
US20230226040A1 (en) Combination therapy comprising an fgfr inhibitor and a kras inhibitor
CN104244952A (zh) 组蛋白脱乙酰酶抑制剂与帕唑帕尼的组合及其用途
US20240207257A1 (en) Combination therapy comprising a pkc inhibitor and a mek inhibitor
HK40084686A (en) Pharmaceutical compositions and methods of using the same for treating cancer
US20240335440A1 (en) Combination therapy comprising a pkc inhibitor and a c-met inhibitor
CA3163122C (en) Combination decitabine and cedazuridine solid oral dosage forms
HK40085734A (en) Solid oral dosage forms of combination of decitabine and cedazuridine
JP2005526787A (ja) 注意欠陥多動性障害の治療のためのベンゾフラン誘導体を含む薬学的組成物及びその使用